NCT05225077

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Dong-A University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Conditions

• Renal Insufficiency, Chronic
• Cardiac Catheterization
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10 MG [Farxiga]	Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.

Timeline

• Start date: 2022-01-01
• Primary completion: 2022-12-31
• Completion: 2023-12-31
• First posted: 2022-02-04
• Last updated: 2022-02-04

Locations

1 site across 1 country: South Korea